anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rice production is severely affected by various diseases such as bacterial leaf blight (BLB), brown spot (BS), false smut (FS), foot rot (FR), rice blast (RB), and sheath blight (SB). In recent years, several quantitative trait loci (QTLs) studies involving different populations have been carried out, resulting in the identification of hundreds of resistance QTLs for each disease. These QTLs can be integrated and analyzed using meta-QTL (MQTL) analysis for better understanding of the genetic architecture underlying multiple disease resistance (MDR). This study involved an MQTL analysis on 661 QTLs (378, 161, 21, 41, 44, and 16 QTLs for SB, RB, BLB, BS, FS, and FR, respectively) retrieved from 50 individual studies published from 1995 to 2021. Of these, 503 QTLs were projected finally onto the consensus map saturated with 6,275 markers, resulting in 73 MQTLs, including 27 MDR-MQTLs conferring resistance to three or more diseases. Forty-seven MQTLs were validated using marker-trait associations identified in published genome-wide association studies. A total of 3,310 genes, including both R and defense genes, were also identified within some selected high-confidence MQTL regions that were investigated further for the syntenic relationship with barley, wheat, and maize genomes. Thirty-nine high-confidence candidate genes were selected based on their expression patterns and recommended for future studies involving functional validation, genetic engineering, and gene editing. Nineteen MQTLs were co-localized with 39 known R genes for BLB and RB diseases. These results could pave the way to utilize candidate genes in a marker-assisted breeding program for MDR in rice.
The present invention provides a kind of medical composition, and it includes fulvestrant, the aqueous solvent of satisfaction (1)~(4) and the pharmaceutically acceptable non-aqueous carriers of satisfaction (A) and (B) that the gross mass relative to medical composition is 8 mass % or more.(1) ethyl alcohol for being 8 mass % or more comprising the gross mass relative to medical composition.(2) comprising relative to medical composition gross mass be 3 mass % or more, be selected from least one of propylene glycol and 1,3 butylene glycol polyalcohol.(3) containing ratio of benzylalcohol is relative to the gross mass of medical composition less than 5 mass %.(4) containing ratio of aqueous solvent is 15~50 mass % relative to the gross mass of medical composition.(A) containing ratio of Ergol is relative to the gross mass of medical composition less than 1 mass %.(B) containing ratio of non-aqueous carrier is 40~75 mass % relative to the gross mass of medical composition.
PURPOSE: Provided is a cosmetic composition for skin care, containing a Mume Fructus extract which activates keratinocyte as a skin cell, promotes keratinization and keeps skin moist. Therefore, the composition is safe to the skin and has excellent skin care effect. CONSTITUTION: The skin cosmetic composition contains 0.01 to 10% by weight of a Mume Fructus extract, based on the total weight of the composition. The Mume Fructus extract is obtained by extracting Mume Fructus, followed by filtration, aging at 0 to 10deg.C for 3 to 10 days and refiltration. The cosmetic composition is formulated into a form selected from a lotion, cream, massage cream, essence or a mask pack. For an example, 1.0% by weight of the Mume Fructus extract is mixed with 4.5% by weight of 1,3-butylene glycol, 5.0% by weight of glycerine, 10.0% by weight of ethanol, 0.1% by weight of oleyl alcohol, 0.5% by weight of Polysorbate 20, 0.1% by weight of propyl paraben, 0.3% by weight of pf.kn-753 and the balance of purified water.
Chlorpromazine and promethazine (C+P), due to their effort to induce a hibernation-like status, has been proved to be neuroprotective for ischemic stroke in pre-clinical experiments. However, whether it is safe and potentially effective in acute ischemic stroke (AIS) patients is currently unknown. The reason might be that the optimal dosage is not defined in AIS treatment. High dosage of C+P might result in hypotension and extrapyramidal symptoms that diminishes its neuroprotective effect. So it is essential to determine a safe and potentially dosage. Another reason might be that patients from previous clinical trials assessing the effectiveness of C+P did not receive reperfusion therapy. In this study，we plan to conduct a 6+2 dose-escalation clinical trial to determine the safety of C+P in AIS patients receiving endovascular thrombectomy. Four dosage groups of C+P will be set(10mg/20mg/50mg/100mg).A minimum of 32 patients will be involved if no drug related severe adverse event(SAE) was observed. A maximum of 64 patients will be required if one SAE is observed in each group. The current study aim to provide a basis for phase Ⅱ clinical trial to further explore the efficacy of C+P in AIS treatmment.
The present invention provides an antimicrobial composition for disinfection of a skin surface in preparation for surgery. The antimicrobial composition comprises parachlorometaxylenol (PCMX) and an anionic surfactant composition which exhibits both a high degree of antimicrobial efficacy and low skin irritability properties. In a preferred embodiment, the composition comprises an anionic surfactant composition comprising a surfactant having a hydrophobic portion consisting of a linear alkyl and a hydrophilic portion having ethoxylation termination with a sulfonate anionic group, and a sarcosine surfactant. A preferred surfactant composition further comprises a foaming anionic surfactant, such as sodium lauryl sulfate. The antimicrobial composition can be used in skin disinfecting formulations, such as scrub formulations and pre-operative skin disinfecting formulations. In one embodiment, the composition comprises about 3.3% parachlorometaxylenol. The composition can be used as a surgical scrub formulation or in various pre-surgical skin disinfecting products, including sponges, swabs and topical application devices.
Bulimia nervosa (BN) is a debilitating psychiatric disorder that primarily affects young women. Empirically supported treatments for BN have been identified but less than half of treated individuals achieve long-term remission from the disorder, possibly because current treatment approaches do not sufficiently account for variables that help maintain the disorder. Psychosocial models of BN emphasize the role of dieting as a proximal cause of binge eating and purging. Dieting has both psychological and biological facets but existing models of BN have overwhelmingly focused on its psychological impact. The investigators have differentiated between a diet-induced long-term energy imbalance (weight suppression (WS), or the difference between one's highest-ever body weight and current weight) and a short-term energy imbalance (current dieting to either lose weight or avoid weight gain). Recent research has shown that WS levels in BN are elevated and that degree of WS predicts the severity of various BN characteristics and its clinical course. Studies of current dieting (CD) to lose weight have found that it is associated with reduced binge eating in BN, a finding that conflicts with prevailing models of the disorder. The proposed research will examine biological (e.g., energy expenditure, neuroendocrine and appetitive hormones) and behavioral (e.g., binge eating and purging) correlates of WS and CD in those with BN. (Relatively few of those with BN report dieting to avoid weight gain but its biological and behavioral correlates will also be examined.) The project will recruit 132 women (66 at Drexel University and 66 at Columbia University) meeting provisional Diagnostic and Statistical Manual-V diagnostic criteria for BN. The investigators will test the hypotheses that 1) CD and elevated WS will be associated with alterations in biological indices of metabolism and appetite, 2) WS will predict greater binge eating and purging, and CD will predict less binge eating, measured using Ecological Momentary Assessment (EMA), and 3) higher real time ratings of daily food restriction intentions will predict a reduced probability of binge eating during the same day but an increased probability of binge eating in subsequent days. Assessments for all participants will include: weight and reported previous highest weight (to calculate WS), the Eating Disorders Examination, 14 days of EMA to assess food restriction intentions, binge eating and purging episodes, three 24-hr food recalls, and resting energy expenditure and metabolic and appetitive hormones (including complete thyroid panel, leptin, ghrelin, cortisol and estradiol). Participants will be asked to return 6 months later for follow-up assessments of weight. This study will elucidate how two common yet largely unexplored types of dieting influence biological and behavioral variables in patients with BN, which could lead to modifications of prevailing models of BN and new strategies for improving treatment outcome.
The invention mainly treats acute and chronic nephritis and urinary tract infection, and has the functions of relieving pain and diminishing inflammation, strengthening kidney and promoting urination, and no sequela is remained after the medicine is taken by patients. The medicine is taken orally according to the medical advice. The main components are No. 1 medicine  rhubarb, tuckahoe, scorpion, etc. No. 2 medicine (slow) cogongrass rhizome, raw licorice, combined spicebush root, dodder seed, etc. The invention has no side effect and is contraindicated for pregnant women.
The count of locations with chronic pain is widely used in research and clinical practice. However, this approach might be too simplistic to fully capture the complexity of chronic pain experiences. This study identified prevalent patterns of chronic pain locations and evaluated their associations with incident dementia among middle-aged and older adults in the UK. Data were from 445,530 participants who were free of dementia at baseline (2006-2010) in the UK Biobank. We calculated the incidence rates of all-cause dementia by the 20 most prevalent combinations of pain locations assessed at baseline. Cox models were utilized to examine the hazard ratio of incident dementia among each of these 20 combinations compared to 3 groups: 1) participants without chronic pain, 2) participants with only a single chronic pain location not included in the combination, and 3) participants with only a single chronic pain location included in the combination. The 3 most prevalent combinations were neck and back (5.7%), back and knee (5.4%), and neck and knee (4.5%). Chronic back, neck, and knee pain was commonly present either individually or simultaneously in combinations associated with higher dementia rates than persons without chronic pain. The combinations involving back, neck, and knee were associated with higher dementia rates than groups with 1 pain location not included in the combination. Chronic pain is not randomly present in body locations. Understanding how different patterns of chronic pain locations relate to dementia provides new insights into dementia prevention through pain relief. PERSPECTIVE: This article unveils chronic pain patterns and dementia risks in the UK Biobank. Chronic pain in back, neck, and knee presents frequently, either individually or in combinations associated with increased dementia rates. Chronic pain combos correlate with diverse dementia rates, guiding targeted prevention strategies through pain management.
A method of diagnosing a patient is carried out by delivering an aerosolized dose of a radioactive formulation to a patient and making a ventilation image of radioactive material deposited in the lung. This image is compared with a separately generated image (perfusion image) taken after injecting radiolabled particles into the pulmonary arterial circulation. Devices, packaging and methodology for creating aerosols are provided which allow for efficient and repeatable delivery of radioaerosols to the lungs of a patient. Devices may be plug-in units or hand-held, self-contained units which are automatically actuated at the same release point in a patient's inspiratory flow cycle. The device is loaded with a container of a radioactive formulation such as  99m  Tc-labelled diethylene-triamine pentaacetic acid (DTPA). Actuation of the device forces the radioactive formulation through a porous membrane of the container which membrane has pores having a diameter in the range of about 0.25 to 6.0 microns. The container includes radioactive shielding in the form of a lead coating and/or a lead surrounding packet. The porous membrane is positioned in alignment with a surface of a channel through which a patient inhales air.
PROBLEM TO BE SOLVED: To obtain the subject low molecular weight promoter usable for treatment of neurodegenerative disease, etc., by making the include a nitrogen monoxide (NO) donor as an active ingredient. SOLUTION: This secretagogue contains a nitrogen monoxide (NO) donor (usually a compound having nitro group designed as a nitric acid medicine or nitro medicine, e.g. sodium nitroprusside) as an active ingredient. The NO donor is preferably spontaneous NO donor [e.g. S-nitroso-N-acetyl-DL- penicillamine or 1-substituted-diazen-1-ium-1,2-dioleate] and the promoter is preferably administered to human in order to treat neurodegenerative diseases. The promoter can be administered by various kinds of administration methods according to a method used for treatment of angina pectoris as an administration method.
Individuals are often required to operate in adverse conditions and may be exposed to prolonged periods of high ambient heat and humidity. High environmental temperatures impair work capacity and increase heat-illness risk. Repeated exposure to heat in a laboratory setting (acclimation) elicits a range of adaptations, which reduce heat illness risk and increase work capacity in the heat. However, traditional approaches to heat acclimation are time consuming, typically requiring daily heat exposures of 1 to 2 hours over \~7 to 10 consecutive days. This can be logistically difficult to implement and impractical, particularly in situations where an individual must be rapidly deployed. Therefore, heat acclimation approaches which reduce the number of days to achieve acclimation may have utility. In addition, recent research studies have suggested that adaptation to heat may improve tolerance to hypoxia (cross-adaptation) and improve aerobic fitness; these effects may also be beneficial in a military context. Therefore, the primary purpose of the proposed research is to determine whether it is possible to achieve a similar degree of heat acclimation to that seen with a traditional longer-term heat acclimation approach by increasing the frequency of heat exposure, utilising multiple daily heat exposures over a smaller number of days. Secondary aims of the research are to examine whether heat acclimation provides cross-adaptation to a hypoxic stressor and whether heat acclimation improves aerobic fitness. Heat acclimation will be evaluated using a range of whole-body (cardiovascular, thermoregulatory, psychophysiological) and biochemical markers.
BACKGROUND: A physically active lifestyle is beneficial during pregnancy. However, little is known about physical activity (PA) behaviour and psychosocial factors in women during and after pregnancy. This study examined exercise behavioural regulation, exercise self-efficacy, health-related quality of life, sickness absence and musculoskeletal pain in pregnant women offered either structured supervised exercise training, motivational counselling on PA, or standard prenatal care in the FitMum randomised controlled trial.
METHODS: Two hundred and eighteen healthy inactive pregnant women were randomised to structured supervised exercise training (n = 87), motivational counselling on PA (n = 86) or standard prenatal care (n = 45). The women answered the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2), the Pregnancy Exercise Self-Efficacy Scale (P-ESES-DK) and the Short Form 36 Health Survey Questionnaire (SF-36) at baseline (gestational age (GA) of max 15 weeks), GA 28 and 34 weeks, and one year after delivery. Sickness absence and low back and/or pelvic girdle pain were likewise reported in questionnaires at baseline and GA 28 weeks.
RESULTS: Participants offered structured supervised exercise training or motivational counselling on PA had higher autonomous motivation for exercise during pregnancy compared with participants receiving standard prenatal care (e.g., difference in intrinsic regulation at GA 28 weeks, structured supervised exercise training vs. standard prenatal care: mean difference in score 0.39 [0.16; 0.64], p < 0.001). Participants offered structured supervised exercise training also had higher exercise self-efficacy during pregnancy (e.g., GA 28 weeks, structured supervised exercise training vs. standard prenatal care: mean difference in score 6.97 [2.05; 12.02], p = 0.005). All participants reported high exercise self-efficacy at baseline and medium exercise self-efficacy during pregnancy and one year after delivery. No differences were found between groups in health-related quality of life, sickness absence or low back and/or pelvic girdle pain during pregnancy. No group differences were found one year after delivery.
CONCLUSION: Structured supervised exercise training and motivational counselling on PA had important effects on autonomous exercise motivation during pregnancy. Exercise self-efficacy was also increased with structured supervised exercise training compared to standard prenatal care. No group differences in health-related quality of life, sickness absence, or pain were found during and after pregnancy. No effects were found one year post-delivery after intervention cessation.
TRIAL REGISTRATION: The study was approved by the Danish National Committee on Health Research Ethics (#H-18011067) and the Danish Data Protection Agency (#P-2019-512). The study adheres to the principles of the Helsinki declaration. Written informed consent was obtained at inclusion.
Group III, will be intervened with continuous stimulation at a frequency of 50 Hz,a pulse width of 200 μs (18) and for a total of 20 minutes. The intensity will be set at the maximum tolerable threshold. In case the patient does not tolerate the treatment, due to increased fatigue, the 50 hertz will be alternated with the 20 hertz in bursts.
The invention specifically relates to a preparation method of a nutritional protection cream for resisting dinitrogen tetroxide. In comparison with wearable breathing masks and the disinfection technology, the nutritional protection cream has not only remarkable effects but also advantages of security, endurance and economy. At present, there is no N2O4 nutritional protection cream published at home and abroad. Therefore, the developed N2O4 nutritional protection cream will have a great application prospect. The preparation method of the nutritional protection cream comprises the following steps of: adding hydrophilic components into deionized water, heating to 70 DEG C, fully stirring to make the mixture fully and uniformly swell and prevent agglomeration, while the emulsification temperature ranges from 70 DEG C to 75 DEG C and the speed and time of homogenization are strictly controlled; adding essence and active matter below 50 DEG C; cooling the emulsification system to nearly room temperature after emulsification; discharging while the discharging temperature depends on the softening temperature of the emulsification system; storing for one day and filling with a filling machine. Multiple tests prove that vitamin C and glutathione can directly react with dinitrogen tetroxide so as to eliminate the toxicity of dinitrogen tetroxide. The minimum contents of vitamin C, glutathione, glycerin and eleaostearic acid in the product provided by the invention are respectively 1.8%, 30%, 10% and 18%, inclusive of deionized water added to 100%.
Since CD4 is the high-affinity receptor for HIV-1, molecules such as CD4-IgG2, which incorporate the gp120 binding region of CD4, have the potential to bind and neutralize all strains of the virus. \[AS PER AMENDMENT 4/25/00: Study results have demonstrated that the product is safe in children, well tolerated, and may have antiviral properties. With these encouraging results in hand, an extra cohort has been added using twice the dose of rCD4-IgG2 as in Cohort I.\]

The study is conducted in two parts. In Part 1 patients receive a single dose of CD4-IgG2 intravenously at 1 of 4 dose levels. A minimum of 3 patients are treated at a given dose level. If none of these 3 patients experience Grade 3 or 4 toxicity, patients are escalated to the next dose level. If any of these 3 patients have life-threatening toxicities or if more than 1 of these 3 patients experience non-life-threatening Grade 3 or 4 toxicities, escalation stops and the prior dose (if any) is considered the maximum tolerated dose (MTD). If 1 of these 3 patients experiences non-life-threatening Grade 3 or 4 toxicities, 3 additional patients are treated at this dose level. If 1 or more of these 3 additional patients has Grade 3 or 4 toxicity, escalation stops. If none of these 3 additional patients has Grade 3 or 4 toxicity, patients are escalated to the next dose level.

Part 2 provides additional data on the safety, toxicity and pharmacokinetics of CD4-IgG2 when given in multiple doses. Patients receive the highest safe dose (MTD) as established in Part 1. Treatment is given intravenously once weekly at Weeks 0, 1, 2, and 3. If insufficient activity is seen at this dose level, 6 additional patients will be enrolled at a higher dose level. Patients who participate in Part 1 may enroll in Part 2 provided they are followed for at least 3 months and meet inclusion criteria for Part 2. If any patient experiences a life-threatening condition due to CD4-IgG2, the study will stop. \[AS PER AMENDMENT 4/25/00: Cohort II receives twice the dose of Cohort I intravenously once weekly at Weeks 0, 1, 2 and 3. Pharmacokinetic samples are obtained at pre-dose and 1 hour after the doses are administered at Weeks 0, 1, and 2; and pre-dose, 1 hour, 24 hours, and Days 3, 7, and 14 after the dose are administered at Week 3. An overnight stay in the hospital is recommended for the first 24 hours. At Weeks 0, 1, 2, and 3, virology testing including HIV-1 RNA is performed with each infusion of CD4-IgG. Follow-up monitoring of patients is done once a month for 4 months for patients in Cohort II.\]
Women in this group wil be followed during 3 years. Echocardiography images, 24-hour ambulatory blood pressure monitoring will be collected.